GETTING MY ABBV-744 BRD4 INHIBITOR CLINICAL EFFICACY IN REFRACTORY CANCERS TO WORK

In Section A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to determine safe dosing program. More individuals might be enrolled with the recognized monotherapy dosign program. In Section B, contributors will obtain oral ruxolitinib and ABBV-744 will likely be offered as "add-on" therapy. In Section C, participants will